Pyridoxine treatment and prevention of hand-and-foot syndrome in patients receiving capecitabine

Journal of Oncology Pharmacy Practice

Volumn 9, Issue 4, 2003, Pages 161-166

  Mortimer, Joanne E ^a   Lauman, Mary Kay ^a   Tan, Benjamin ^a   Dempsey, Cindy L ^b   Shilington,, Alicia C ^b   Hutchins, Kellie S ^b  

^a Sentara Cancer Resource Centers   (United States)

^b Epi Q   (United States)

Author keywords

Capecitabine; Hand and foot syndrome; Pyridoxine; Pyridoxine prophylaxis ; Pyridoxine treatment

Indexed keywords

ALOE VERA EXTRACT; CAPECITABINE; CORN HUSKER; CYCLOPHOSPHAMIDE; EMOLLIENT AGENT; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; HYDROCORTISONE; LANOLIN; LANOLIN ALCOHOL; METHOTREXATE; PACLITAXEL; PREDNISONE; PYRIDOXINE; UDDERLY SMOOTH;

ADULT; AGED; ALOPECIA; ARTICLE; BREAST CANCER; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DIARRHEA; DIGESTIVE SYSTEM CANCER; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; INCIDENCE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; STOMATITIS;

EID: 0344034808     PISSN: 10781552     EISSN: None     Source Type: Journal    
DOI: 10.1191/1078155203jp116oa     Document Type: Article

References (21)

1. Leichman CG, Leichman L, Spears CP et al Prolonged continuous infusion of fluorouracil with weekly bolus leucovorin: a phase II study in patients with disseminated colorectal cancer. J Natl Cancer Inst 1993; 85: 41-44.
2. Lokich JD, Moore C. Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome. Ann Intern Med 1984; 106: 798-99.
3. Meta-Analysis Group in Cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol 1998; 16: 3537-41.
4. Sobero AF, Aschele C, Bertino JR. Fluorouracil in colorectal cancer - a tale of two drugs: implications for biochemical modulation. J Clin Oncol 1997; 15: 368-81.
5. Tralongo P, Di Mari A, Scibilia G et al. Prolonged 5-fluorouracil infusion in patients with metastatic colon cancer pretreated with bolus schedule of the same agent. Anticancer Res 1995; 15: 635-38.
6. Mortimer JE, Anderson I. Weekly fluorouracil and high-dose leucovorin: efficacy and treatment of cutaneous toxicity. Cancer Chemother Pharmacol 1990; 26: 449-52.
7. American Society of Health-System Pharmacists. AHFS drug information 2001. Bethesda, MD: ASHP, 2001.
8. Mrozek-Orlowski ME, Frye DK, Sanborn HM, Capecitabine: nursing implications of a new oral chemotherapeutic agent. Oncol Nurs Forum 1999; 26: 753-62.
9. Nagore E, Insa A, Sanmartin O. Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand foot') syndrome. Incidence, recognition and management. Am J Clin Dermatol 2000; 1: 225-34.
10. Fabian CJ, Molina R, Slavik M et al. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. Invest New Drugs 1990; 8: 57-63.
11. Cancer Therapy Evaluation Program. Common toxicity criteria [computer program]. Version 2.0 Bethesda, MD: National Cancer Institute; 1999.
12. Budman DR, Meropol NJ, Reigner B et al. Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J Clin Oncol 1998; 16: 1795-802.
13. Hoff PM, Ansari R, Batist G et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 695 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001l; 19: 2282-92.
14. Blum JL, Jones SE, Buzdar AU et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999; 17: 485-93.
15. Gradishar WJ. Clinical status of capecitabine in the treatment of breast cancer. Oncology 2001; 15: 69-72.
16. O'Shaughnessy J. Clinical experience of capecitabine in metastatic breast cancer. Eur J Cancer 2002; 38(suppl 2): 10-14.
17. O'Shaughnessy J, Moiseyenko V, Bell D et al. A randomized phase II study of Xeloda (capecitabine) vs CMF as first line chemotherapy of breast cancer in women aged > 55 years. ASCO Progam/Proceeding Abstracts 1998; 17: 103.
18. O'Reilly SM, Moiseyenko V, Talbot DC et al. A randomized phase II study of Xeloda™ (capecitabine) vs paclitaxel in breast cancer patients failing previous anthracycline therapy. ASCO Program/Proceeding Abstracts 1998; 17: 163.
19. Abushullaih S, Saad ED, Munsell M, Hoff PM. Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience. Cancer Invest 2002; 20: 3-10.
20. Milano G, Etienne MC, Cassuto-Viguier E et al. Influence of sex and age on fluorouracil clearance. J Clin Oncol 1992; 10: 1171-75.
21. Sloan JA, Goldberg RM, Sargent DJ et al. Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol 2002; 20: 1491-98.